25.11.2016 • NewsDede WillamsBASFTDI

BASF TDI Plant Goes Down Again

TDI plant at Ludwigshafen site
TDI plant at Ludwigshafen site

Problems with its new EUR 1 billion TDI complex at Ludwigshafen, Germany, continue to plague BASF. On Nov. 23, the world’s largest chemical producer said the facility with nameplate capacity to produce 300,0000 t/y of the polyurethane feedstock had to be taken off line again due to an unspecified technical defect. The mammoth production complex, inaugurated almost exactly a year ago, has still not reached full run. Altogether it consists of eight separate plants that, among other things, produce precursors for the isocyanate. Each unit had to be individually started up, the group said earlier this year, explaining why the technical issues are so complex.

In its statement announcing this week’s breakdown, BASF said the impacted equipment in the closed safety chamber of the TDI complex will be analyzed and, if necessary, replaced. Before the plant is restarted, the group said it will “reexamine all relevant parts” in cooperation with the respective authorities. Authorities in the German state of Rhineland Palatine have already inspected the production site following a series of glitches this year, including the accidental release of nitrogen oxide and phosgene.

Since last month, the Ludwigshafen site has faced numerous production outages and BASF had to declare force majeure for several products after the Oct. 17 fire and explosion killed four people. Authorities and BASF are investigating this incident separately. The market for TDI in Europe remains tight, independently of the problem at BASF.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.